Washington, D.C. — June 30, 2026 — The U.S. House Select Committee on the Strategic Competition between the United States and the Chinese Communist Party has launched a national security review into the overseas clinical trial activities of several leading American pharmaceutical companies, raising new questions about the intersection of biotechnology, healthcare innovation, and geopolitical competition.

John Moolenaar, Chairman of the House Select Committee on the Chinese Communist Party, announced that formal inquiry letters had been sent to five major U.S. pharmaceutical companies — Merck & Co., AbbVie, Eli Lilly and Company, Pfizer, and Bristol Myers Squibb — requesting information regarding their clinical trial operations in China.

According to the committee, the investigation will focus on how U.S. pharmaceutical companies conduct clinical research in China, including data management, patient information protection, regulatory cooperation, and potential risks related to the transfer of sensitive biomedical data. The committee stated that the review aims to assess whether overseas clinical research activities could create vulnerabilities affecting U.S. national security and long-term technological competitiveness.

Growing Concerns Over Biomedical Data and Strategic Competition

The investigation comes amid increasing attention from U.S. policymakers toward biotechnology as a strategic industry. In recent years, Washington has emphasized that advanced technologies, including artificial intelligence, semiconductor manufacturing, genetic technologies, and biomedical innovation, are increasingly connected to national security considerations.

Clinical trials generate valuable scientific information, including patient health data, biological samples, disease characteristics, and drug response information. As global pharmaceutical development becomes increasingly internationalized, many multinational companies conduct clinical studies across multiple regions to accelerate drug development, improve patient recruitment, and meet regulatory requirements.

China has become one of the world’s largest markets for pharmaceutical research and clinical trials. The country’s large patient population, expanding healthcare infrastructure, and growing biotechnology sector have made it an important location for global drug development programs.

However, U.S. lawmakers have raised concerns about how biomedical data collected overseas is stored, processed, and potentially shared. The committee’s inquiry reflects broader debates in Washington about balancing international scientific collaboration with data security and strategic interests.

Impact on U.S. Pharmaceutical Industry

The investigation could create additional compliance requirements for pharmaceutical companies operating internationally. Companies may face increased scrutiny regarding clinical trial partnerships, data transfer agreements, cybersecurity protections, and relationships with overseas research organizations.

Industry experts note that global clinical trials are essential for modern drug development. Many breakthrough medicines rely on international collaboration, diverse patient populations, and multinational regulatory processes. Pharmaceutical companies argue that international research partnerships help accelerate the availability of innovative treatments for patients worldwide.

At the same time, companies may need to strengthen transparency around overseas operations and demonstrate that clinical research activities comply with U.S. regulations and data protection standards.

The five companies named in the investigation represent some of the largest pharmaceutical organizations in the world, with extensive global research networks and significant investments in drug discovery. Their responses to the congressional inquiries could influence future discussions regarding the relationship between pharmaceutical innovation and national security policy.

Potential Changes in Global Life Science Collaboration

The investigation may also have broader implications for the global life sciences ecosystem. Over the past decade, pharmaceutical research has become increasingly interconnected, with companies relying on international talent, research institutions, manufacturing partners, and clinical trial sites.

A more restrictive regulatory environment could affect how multinational companies design future clinical development strategies. Some organizations may consider expanding domestic research capabilities, diversifying international partnerships, or increasing investment in data security infrastructure.

Analysts believe that the challenge for policymakers will be finding a balance between protecting national interests and maintaining the global cooperation necessary for scientific progress. Excessive restrictions could slow innovation, while insufficient oversight could create potential security risks.

Looking Ahead

The House Select Committee’s investigation represents another step in the evolving U.S.-China technology and economic competition. As biotechnology becomes increasingly recognized as a strategic asset, pharmaceutical companies are likely to face greater expectations regarding transparency, security, and supply chain resilience.

The responses from Merck, AbbVie, Eli Lilly, Pfizer, and Bristol Myers Squibb will be closely watched by policymakers, industry leaders, and investors. The outcome of the investigation could shape future policies governing international clinical research, biomedical data management, and cross-border scientific cooperation.

For the pharmaceutical industry, the issue highlights a new reality: innovation is no longer evaluated only through the lens of scientific achievement and commercial success, but also through the perspective of national security, data governance, and geopolitical strategy.